Brianna L Norton1, William N Southern2, Meredith Steinman3, Bryce D Smith4, Joseph Deluca3, Zachary Rosner3, Alain H Litwin3. 1. Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York; Division of General Internal Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York. Electronic address: bnorton@montefiore.org. 2. Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York; Division of Hospital Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York. 3. Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York; Division of General Internal Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York. 4. Division of Viral Hepatitis, Centers for Disease Control and Prevention, National Center for HIV/Viral Hepatitis/STD/TB Prevention, Atlanta, Georgia.
Abstract
BACKGROUND & AIMS: National hepatitis C virus (HCV) screening guidelines recommended 1-time testing of persons born between 1945 and 1965. METHODS: We performed a retrospective study to compare care milestones achieved by HCV-infected patients identified by birth cohort versus risk-based screens. RESULTS: We determined the proportions of patients newly identified with HCV infection who met care milestones (viral load, referral to and evaluation by a specialist, offer of treatment, initiation of treatment, and sustained viral response) and the time it took to reach them. We found no differences in HCV care milestones for patients identified via birth cohort testing versus risk-based screening. Overall, only 43% of HCV antibody-positive patients were referred to care, and less than 4% started treatment. The time to each care milestone was lengthy and varied greatly; treatment was initiated in a median of 308 days. CONCLUSIONS: Although birth cohort testing will likely increase identification of patients with HCV infection, it does not seem to increase the number of patients that meet management milestones. New methods are needed to increase access to care and establish efficient models of health care delivery.
BACKGROUND & AIMS: National hepatitis C virus (HCV) screening guidelines recommended 1-time testing of persons born between 1945 and 1965. METHODS: We performed a retrospective study to compare care milestones achieved by HCV-infectedpatients identified by birth cohort versus risk-based screens. RESULTS: We determined the proportions of patients newly identified with HCV infection who met care milestones (viral load, referral to and evaluation by a specialist, offer of treatment, initiation of treatment, and sustained viral response) and the time it took to reach them. We found no differences in HCV care milestones for patients identified via birth cohort testing versus risk-based screening. Overall, only 43% of HCV antibody-positive patients were referred to care, and less than 4% started treatment. The time to each care milestone was lengthy and varied greatly; treatment was initiated in a median of 308 days. CONCLUSIONS: Although birth cohort testing will likely increase identification of patients with HCV infection, it does not seem to increase the number of patients that meet management milestones. New methods are needed to increase access to care and establish efficient models of health care delivery.
Authors: Alain H Litwin; Bryce D Smith; Mari-Lynn Drainoni; Diane McKee; Allen L Gifford; Elisa Koppelman; Cindy L Christiansen; Cindy M Weinbaum; William N Southern Journal: Dig Liver Dis Date: 2012-02-18 Impact factor: 4.088
Authors: David B Rein; John S Wittenborn; Cindy M Weinbaum; Miriam Sabin; Bryce D Smith; Sarah B Lesesne Journal: Dig Liver Dis Date: 2010-06-17 Impact factor: 4.088
Authors: Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward Journal: MMWR Recomm Rep Date: 2012-08-17
Authors: W N Southern; M-L Drainoni; B D Smith; C L Christiansen; D McKee; A L Gifford; C M Weinbaum; D Thompson; E Koppelman; S Maher; A H Litwin Journal: J Viral Hepat Date: 2010-05-20 Impact factor: 3.728
Authors: Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; John W Ward; Scott D Holmberg Journal: Ann Intern Med Date: 2012-02-21 Impact factor: 25.391
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg Journal: Ann Intern Med Date: 2014-03-04 Impact factor: 25.391
Authors: Dena P Blanding; William P Moran; John Bian; Jingwen Zhang; Justin Marsden; Patrick D Mauldin; Don C Rockey; Andrew D Schreiner Journal: J Investig Med Date: 2020-11-17 Impact factor: 2.895
Authors: Jason Zucker; Justin G Aaron; Daniel J Feller; Jacek Slowikowski; Henry Evans; Matthew L Scherer; Michael T Yin; Peter Gordon Journal: Open Forum Infect Dis Date: 2018-07-03 Impact factor: 3.835